Douglas Hunt
General Counsel at PUMA BIOTECHNOLOGY, INC.
Net worth: 446 177 $ as of 2024-06-29
Profile
Douglas Hunt is currently the Chief Regulatory Affairs Officer at Puma Biotechnology, Inc. He previously worked as the Executive Director-Therapeutic Area at Amgen, Inc. from 2000 to 2008.
From 2008 to 2015, he served as the Vice President-Global Regulatory Affairs at Baxter Healthcare Corp.
He then worked as the VP-Regulatory Affairs & Quality Assurance at ArmaGen, Inc. from 2015 to 2017.
Mr. Hunt completed his undergraduate degree at the University of Portsmouth.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
PUMA BIOTECHNOLOGY, INC.
0.28% | 2024-07-01 | 136,864 ( 0.28% ) | 446 177 $ | 2024-06-29 |
Douglas Hunt active positions
| Companies | Position | Start |
|---|---|---|
| PUMA BIOTECHNOLOGY, INC. | General Counsel | 2017-12-31 |
Former positions of Douglas Hunt
| Companies | Position | End |
|---|---|---|
ArmaGen, Inc.
 ArmaGen, Inc. Hospital/Nursing ManagementHealth Services ArmaGen, Inc. engages in operation of a clinical stage biotechnology company focused on developing revolutionary therapies for severe neurological disorders. Its products include AGT-110-Brain-penetrating biologic tumor necrosis factor inhibitor (TNFI) for Alzheimer's disease, AGT-115-Brain-penetrating erythropoietin (EPO) for stroke, AGT-160-Brain penetrating anti-amyloid antibody (AAA) for Alzheimer's disease and AGT-181-Brain-penetrating iduronidase (IDUA) for Mucopolysaccharidosis (MPS) Type I (Hurler's syndrome). The company was founded by William M. Pardridge and Ruben J. Boado in 2003 and is headquartered in San Diego, CA. | General Counsel | 2017-11-30 |
Baxter Healthcare Corp.
 Baxter Healthcare Corp. Medical SpecialtiesHealth Technology Baxter Healthcare Corp. develops, manufactures, and distributes hospital supplies and medical technologies. It distributes medical treatment options for conditions such as hemophilia, immune disorders, kidney disease, cancer, and trauma. The company was founded on June 21, 1967 and is headquartered in Deerfield, IL. | General Counsel | 2014-12-31 |
| AMGEN INC. | Corporate Officer/Principal | 2008-06-30 |
Training of Douglas Hunt
| University of Portsmouth | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| PUMA BIOTECHNOLOGY, INC. | Health Technology |
| AMGEN INC. | Health Technology |
| Private companies | 2 |
|---|---|
ArmaGen, Inc.
ArmaGen, Inc. Hospital/Nursing ManagementHealth Services ArmaGen, Inc. engages in operation of a clinical stage biotechnology company focused on developing revolutionary therapies for severe neurological disorders. Its products include AGT-110-Brain-penetrating biologic tumor necrosis factor inhibitor (TNFI) for Alzheimer's disease, AGT-115-Brain-penetrating erythropoietin (EPO) for stroke, AGT-160-Brain penetrating anti-amyloid antibody (AAA) for Alzheimer's disease and AGT-181-Brain-penetrating iduronidase (IDUA) for Mucopolysaccharidosis (MPS) Type I (Hurler's syndrome). The company was founded by William M. Pardridge and Ruben J. Boado in 2003 and is headquartered in San Diego, CA. | Health Services |
Baxter Healthcare Corp.
Baxter Healthcare Corp. Medical SpecialtiesHealth Technology Baxter Healthcare Corp. develops, manufactures, and distributes hospital supplies and medical technologies. It distributes medical treatment options for conditions such as hemophilia, immune disorders, kidney disease, cancer, and trauma. The company was founded on June 21, 1967 and is headquartered in Deerfield, IL. | Health Technology |
- Stock Market
- Insiders
- Douglas Hunt
